Innovators in Cancer Immunology: Lymphoma
珀金埃尔默网站上的Cookie
珀金埃尔默使用cookies来确保我们为您提供在我们网站上的最佳体验。 这可能包括来自第三方网站的cookies。 如果您不改变您的设置点击继续,我们会认为您同意接收本网站的cookies。 您可以随时更改您的Cookie设置。 要了解更多信息,请查看我们的Cookie政策,其中包含有关如何管理Cookie的信息。

Innovators in Cancer Immunology: Lymphoma

June 16, 2017

Innovators in Cancer Immunology: Lymphoma

Skeleton

Scott J. Rodig, MD, PhD
Associate Professor, Pathology, Harvard Medical School
Associate Pathologist, Pathology, Brigham And Women's Hospital, Boston, MA

To advance the understanding of disease mechanisms in cancer, it is critical that researchers see everything a tumor has to show them. Leveraging PerkinElmer’s Phenoptics Quantitative Pathology Research Solutions, researchers are now visualizing and measuring tumor cells and multiple immune-cell phenotypes simultaneously for the first time in formalin-fixed paraffin-embedded (FFPE) tissue.

Because of Phenoptics’ integration of multiplexed immunohistochemistry and imaging, leading scientists are now able to quantitatively capture systems biology data in cellular detail. What follows are brief profiles of some of these Innovators in Cancer Immunology and how they are using Phenoptics to discover new insights into the complexity of immune-cancer interactions that affect countless millions of patients around the world.

Dr. Scott Rodig is a hematological pathologist at Brigham and Women’s Hospital in Boston, MA. He has had a long interest in untangling the complex interactions among Hodgkin’s tumors and their associated stroma to both gain insights into the tumor pathogenesis as well as to develop novel tissue biomarkers for tracking these cells. Much of Dr. Rodig’s research is made possible with Phenoptics.


更多故事关于 生命科学, 病理研究

Innovators in Cancer Immunology: Breast Cancer

Cancer researchers are uncovering new insights using our Phenoptics™ Quantitative Pathology Research Solutions. In a breast cancer case study, Dr. Rimm uses this...